Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Cytogenet Genome Res ; 137(1): 22-30, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22796655

RESUMEN

The karyotypes of pseudoscorpions of the family Atemnidae (Arachnida: Pseudoscorpiones) were studied for the first time. Karyotype data for 7 species have been obtained. The diploid chromosome numbers of most species considerably exceed the numbers reported in pseudoscorpions so far, with males ranging between 65 and 143. In spite of this, the sex chromosome system of atemnids is characterized by the same features that are found in the majority of other pseudoscorpions with an X0 system; the X chromosome is metacentric and is the largest chromosome or one of the largest chromosomes of the karyotype. Male meiotic cells of Atemnus politus contain 1 or 2 autosome multivalents; most specimens had 2 multivalents. The multivalents were composed of 4, 6, 8 or 10 chromosomes. Multivalent number and structure was consistent within each of the studied individuals. The same number of chromosomes in all of the males examined suggests that multivalents are generated by reciprocal translocations. The high diversity of multivalents suggests considerable range of translocation heterozygosity in the studied population.


Asunto(s)
Arácnidos/genética , Cromosomas , Animales , Cariotipificación
2.
Transfus Med ; 20(2): 118-22, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19708894

RESUMEN

Major obstetric haemorrhage (MOH) is the main cause of severe maternal morbidity, incidence being estimated at 4.5 per 1000 deliveries. Cases are not routinely registered in the Netherlands. The objective of this study is to quantify the degree of underreporting of MOH in a large nationwide survey of severe acute maternal morbidity in the Netherlands (LEMMoN) and to estimate the true incidence of MOH in the Netherlands. Retrospective cross-match of the LEMMoN-database with the databases of local blood transfusion laboratories in 65 of 98 hospitals in the Netherlands during a 20-month period, using the capture-recapture method was used. From 16 of 65 centres, the reported transfusion data could not be confirmed by a local obstetrician for logistical reasons. These centres were excluded leaving 49 hospitals available for final analysis. In both databases together, 1018 unique cases of MOH were identified. Underreporting to LEMMoN was 35%. Hence, the true incidence of MOH in the Netherlands is at least 6.1 instead of 4.5 per 1000 deliveries. The estimated underreporting of MOH of 35% is considerable. Underreporting is inherent to large observational multicentre studies and should be anticipated and quantified to facilitate fair comparison of epidemiologic data.


Asunto(s)
Encuestas Epidemiológicas , Complicaciones del Trabajo de Parto/epidemiología , Hemorragia Uterina/epidemiología , Adulto , Transfusión Sanguínea/estadística & datos numéricos , Bases de Datos Factuales , Embolización Terapéutica/estadística & datos numéricos , Estudios de Factibilidad , Femenino , Registros de Hospitales/normas , Registros de Hospitales/estadística & datos numéricos , Hospitales/estadística & datos numéricos , Humanos , Histerectomía/estadística & datos numéricos , Incidencia , Laboratorios/estadística & datos numéricos , Países Bajos/epidemiología , Complicaciones del Trabajo de Parto/cirugía , Complicaciones del Trabajo de Parto/terapia , Servicio de Ginecología y Obstetricia en Hospital/estadística & datos numéricos , Proyectos Piloto , Embarazo , Arteria Uterina , Hemorragia Uterina/cirugía , Hemorragia Uterina/terapia
3.
Leukemia ; 9(7): 1282-4, 1995 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7630204

RESUMEN

The oncoprotein bcl-2 can be expressed in malignant plasma cells and might play a role in the prevention of corticosteroid-mediated apoptosis, thereby prolonging survival of the myeloma cells. We retrospectively investigated whether bcl-2 expression in bone marrow plasma cells measured by two-color fluorescence for immunoglobulin light chains would be related to survival duration in patients suffering from multiple myeloma. In all patients the large majority of plasma cells expressed bcl-2 (median 91%, range 74-100%). Contrary to our expectations, a tendency was observed toward higher percentages bcl-2+ plasma cells in patients with a long survival (more than 5 years, n = 9) vs patients who died from refractory myeloma within a year of diagnosis (n = 7). This tendency was found even when analysis was extended to include four patients in the short diagnosis group (n = 11) who had received chemotherapy prior to bone marrow examination.


Asunto(s)
Mieloma Múltiple/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Mieloma Múltiple/mortalidad , Células Plasmáticas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2 , Estudios Retrospectivos , Tasa de Supervivencia
4.
Ned Tijdschr Geneeskd ; 148(1): 37-9, 2004 Jan 03.
Artículo en Neerlandesa | MEDLINE | ID: mdl-14750454

RESUMEN

A 77-year-old male was diagnosed with immunohaemolytic anaemia. He presented with fever, jaundice and oliguric renal insufficiency. He had been taking diclofenac for three days. Additional examinations and tests revealed a Coombs-positive haemolytic anaemia and thrombopenia. The micro-card gel-agglutination test demonstrated antibodies against diclofenac metabolites. After discontinuation of diclofenac and short-term treatment with prednisone and haemodialysis for two days, the patient made an almost full recovery. Haemolytic anaemia caused by diclofenac is rare. It can be caused by autoantibodies against erythrocytes and complement-fixing antibodies that bind to erythrocytes only in the presence of diclofenac or its metabolites. A timely diagnosis-supported by the appropriate laboratory tests--is of critical importance in this rare but extremely serious complication of the use of diclofenac. The treatment consists of withdrawal of diclofenac and supportive measures, possibly in combination with immunosuppressants.


Asunto(s)
Anemia Hemolítica/inducido químicamente , Antiinflamatorios no Esteroideos/efectos adversos , Autoanticuerpos/inmunología , Diclofenaco/efectos adversos , Anciano , Anemia Hemolítica/inmunología , Eritrocitos/inmunología , Humanos , Masculino , Prednisona/uso terapéutico , Diálisis Renal , Factores de Tiempo , Resultado del Tratamiento
8.
Transfus Med ; 17(3): 182-6, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17561859

RESUMEN

Once thawed, fresh-frozen plasma (FFP) should be used, according to guidelines, within 24 h. In hospital practice, this may be associated with wastage. This study has been performed to investigate the coagulation levels of thawed quarantine FFP as used in the Netherlands. Five units of quarantine FFP, obtained by plasmapheresis, were thawed and by sterile docking divided into satellite bags (SB). SB 2-4 were stored at room temperature (RT) for, respectively, 1, 3 and 6 h and SB 5-9 at 4 degrees C for 6, 12 and 24 h and 1 and 2 weeks. At each time point, activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, factor V (FV), factor VIII (FVIII) and ADAMTS13 activity were measured. During storage at RT for up to 6 h, no major differences were found in the levels of FV, PT, fibrinogen and ADAMTS13 activity. FVIII activity showed a decrease of 16% and the APTT was prolonged by 6%. During storage at 4 degrees C for 2 weeks, FV and FVIII were reduced by 35 and 45%, respectively. The APTT and PT were prolonged by 17 and 15%, respectively. Fibrinogen was decreased by 8%. No change in ADAMTS13 activity was found. FFP stored at RT for 6 h or at 4 degrees C for 2 weeks can provide sufficient support for adequate haemostasis except for patients with a known deficiency for FVIII and can be used for plasmapheresis in patients with thrombotic thrombocytopenic purpura (TTP).


Asunto(s)
Coagulación Sanguínea , Plasma/fisiología , Factor V/análisis , Factor VIII/análisis , Fibrinógeno/análisis , Fibrinólisis , Congelación , Humanos , Tiempo de Tromboplastina Parcial , Tiempo de Protrombina , Temperatura , Tromboplastina/análisis
9.
Transfusion ; 33(9): 735-8, 1993 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8212120

RESUMEN

A pilot study was performed on the storage of plasma and cryosupernatant plasma at 4 degrees C for up to 28 days. Eight bags, four of CPD fresh-frozen plasma (FFP) and four of CPD cryosupernatant plasma (CSP, plasma without cryoprecipitate), were sampled during storage for assays of pH; factors V, VIII, IX, and XI; fibrinogen; prothrombin time; activated partial thromboplastin time (APTT); plasma protein electrophoresis; viscosity; and C1q binding. No changes were found in viscosity or the plasma protein electrophoretic pattern, and there was no detectable immune complex formation. The fibrinogen concentration remained constant, and the prothrombin time showed a gradual increase of 2.5 seconds for both groups of plasma. The labile coagulation factor V decreased gradually for FFP and CSP to 58 and 64 percent of its initial value, respectively (51 +/- 8% and 54 +/- 6% of the value of fresh pooled plasma). Factor VIII decreased to 36 percent of its initial value in FFP (48 +/- 14% of fresh pooled plasma). In CSP, factor VIII decreased after 28 days to 7 percent of its initial value (7 +/- 1% of fresh pooled plasma). The APTT increased for FFP from 28 to 35.8 +/- 1.1 seconds and for CSP from 36 to 49.5 +/- 4.9 seconds. The only chemical change observed for both plasmas was a rise in pH, from 7.27 to 7.56, after 28 days. The results of this pilot study indicate that FFP can be stored at 4 degrees C for 28 days with sufficient recovery of coagulation factors to maintain hemostasis.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Factores de Coagulación Sanguínea/análisis , Conservación de la Sangre , Criopreservación , Factor VIII/análisis , Fibrinógeno/análisis , Plasma/química , Factor IX/análisis , Factor V/análisis , Factor XI/análisis , Humanos , Concentración de Iones de Hidrógeno , Tiempo de Tromboplastina Parcial , Proyectos Piloto , Tiempo de Protrombina , Factores de Tiempo
10.
Clin Chem ; 25(6): 918-23, 1979 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-445827

RESUMEN

We describe a multi-point method for the determination of the serum enzyme activity 5'-nucleotidase by means of an NADH sensor reaction. Studies show that the assay may be carried out in one step, without preincubation, by using a GEMSAEC Fast Analyzer.


Asunto(s)
Nucleotidasas/sangre , Autoanálisis , Centrifugación/métodos , Humanos , Cinética , Espectrofotometría Ultravioleta/métodos
11.
Vox Sang ; 62(1): 49-52, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1580067

RESUMEN

The Lutheran blood group system consists of several genes of which Lua and Lub are the best characterized. Over 98% of the Western population is Lu (b+), and consequently antibody formation against Lub is rare. Cases reported in the literature suggest that the expression of Lutheran antigens on red cells of the newborn is weak, and Lutheran antibodies are not known to have caused severe haemolytic disease of the newborn. We describe a case of anti-Lub immunization during pregnancy. Despite increasing anti-Lub antibody titre and antibody-dependent, cell-mediated cytotoxic activity of the anti-Lub, two parameters associated with haemolytic disease of the newborn, the baby did not suffer from erythroblastosis.


Asunto(s)
Anticuerpos/análisis , Citotoxicidad Celular Dependiente de Anticuerpos/inmunología , Eritroblastosis Fetal/diagnóstico , Isoanticuerpos/sangre , Sistema del Grupo Sanguíneo Lutheran/inmunología , Adulto , Eritroblastosis Fetal/inmunología , Femenino , Humanos , Recién Nacido , Reproducibilidad de los Resultados
12.
Vox Sang ; 63(1): 23-30, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1413660

RESUMEN

There is almost general agreement that removal of leukocytes from blood components reduces the incidence of HLA-antibody formation and refractoriness to random platelet transfusions. Recently filters have become available, which are able to reduce leukocyte contamination in platelet suspensions with acceptable platelet loss. We evaluated a cellulose acetate (CA) and a polyester (PE) filter, and stored buffy coat-derived platelet suspensions after filtration. Both filters are effective for the removal of leukocytes to levels below 5 x 10(6) per transfusate. For the CA filter, platelet recovery was 73 +/- 13% yielding 256 +/- 53 x 10(9) platelets per transfusate from 6 donors. For the PE filter, platelet recovery was 90 +/- 9% and 327 +/- 51 x 10(9) platelets per transfusate. When a loading dose of less than 5 x 10(8) leukocytes was applied, 98% of the CA-filtered suspensions and 100% of the PE-filtered suspensions contained less than 5 x 10(6) residual leucocytes. In 123 patients transfusion results of CA-filtered platelet suspensions stored for 72 h, were compared with those obtained by non-stored, non filtered, random platelet suspensions which had been leukocyte depleted by differential centrifugation. Platelet increments 1 and 20 h after transfusion showed no statistical difference between CA-filtered platelet transfusions stored for 72 h and non-stored, non-filtered platelet transfusions. In a new cohort of 117 patients, two filters and various postfiltration storage times were compared. Using both filters, the 1-hour posttransfusion increments decreased to approximately 60% after 96 h of storage compared to results of storage periods of 72 h or less.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Transfusión Sanguínea , Transfusión de Plaquetas , Plaquetoferesis , Trombocitopenia/terapia , Tiempo de Sangría , Humanos , Concentración de Iones de Hidrógeno , Recuento de Plaquetas , Plaquetoferesis/métodos
13.
Circulation ; 97(6): 562-8, 1998 Feb 17.
Artículo en Inglés | MEDLINE | ID: mdl-9494026

RESUMEN

BACKGROUND: Leukocytes in transfused blood are associated with several posttransfusion immunomodulatory effects. Although leukocytes play an important role in reperfusion injury, the contribution of leukocytes in transfused blood products has not been investigated. To estimate the role and the timing of leukocyte filtration of red cells in cardiac surgery, we performed a randomized study. METHODS AND RESULTS: Patients scheduled for cardiac surgery were randomly allocated to receive either packed cells without buffy coat (PC, n = 306), fresh-filtered units (FF, n = 305), or stored-filtered units (SF, n = 303) when transfusion was indicated. We evaluated the periods of hospitalization and stay at the intensive care unit, and the occurrences of postoperative complications up to 60 days after surgery. The average hospital stay was 10.7 days, of which 3.2 days were in the intensive care unit, without significant differences between the groups. In the PC trial arm, 23.0% of the patients had infections versus 16.9% and 17.9% of the patients in the leukocyte-depleted trial arms (P=.13). Within 60 days, 45 patients had died, 24 patients in the PC trial arm (7.8%), versus 11 (3.6%) and 10 (3.3%) patients in the FF and SF trial arms, respectively (P=.015). CONCLUSIONS: In cardiac surgery patients, especially when more than three blood transfusions are required, leukocyte depletion by filtration results in a significant reduction of the postoperative mortality that can only partially be explained by the higher incidence of postoperative infections in the PC group.


Asunto(s)
Transfusión Sanguínea/métodos , Procedimientos Quirúrgicos Cardíacos , Filtración , Complicaciones Posoperatorias/mortalidad , Anciano , Formación de Anticuerpos , Infecciones Bacterianas/mortalidad , Femenino , Antígenos HLA/inmunología , Humanos , Tiempo de Internación , Leucocitos , Masculino , Persona de Mediana Edad , Factores de Riesgo , Estadística como Asunto
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda